Outcome of eribulin as a late treatment line for Thai metastatic breast cancer patients

Figures & data

Table 1 Patients and cancer characteristics

Covariates	Overall (N = 30), n (%)
Age (years)
Median age (IQR)	56 (52–59)
<50	4 (13)
≥50	26 (87)
Subtypes
Luminal A	5 (17)
Luminal B	8 (27)
HER2	6 (20)
TN	11 (36)
Number of chemotherapies prior to eribulin
≤4	15 (50)
>4	15 (50)
Number of metastatic sites
<3	14 (47)
≥3	16 (53)

Abbreviations: IQR, interquartile range; TN, triple negative.

Table 2 Univariable and multivariable Cox proportional hazard regression analyses

Covariates	Univariable analysis			Multivariable analysis
	HR	95% CI	P-value	aHR	95% CI	P-value
Age (years)			0.100			0.134
<50	1.00			1.00
≥50	2.49	0.74–8.40		2.54	0.75–8.62
Tumor subtype			0.040
Luminal A	1.00
Luminal B	0.35	0.11–1.16
HER2	2.14	0.61–7.53
TN	0.65	0.22–1.92
TN			0.500
No	1.00
Yes	1.33	0.58–3.02
Number of chemotherapies prior to eribulin			0.009			0.046
≤4	1.00			1.00
>4	2.87	1.30–6.33		1.29	1.00–1.65
Number of metastatic sites			0.630
<3	1.00
≥3	0.83	0.40–1.75

Abbreviations: HR, hazard ratio; aHR, adjusted hazard ratio; TN, triple negative.

Figure 1 Kaplan–Meier estimates of PFS.

Abbreviation: PFS, progression-free survival.

Figure 2 Kaplan–Meier estimates of PFS subgroup analysis between different numbers of prior chemotherapies.

Abbreviation: PFS, progression-free survival.

Table 3 Hematologic AEs

Covariates	Number of chemotherapies prior to eribulin		Total (N = 30)	P-value
	≤4	>4
Leukopenia, n (%)				>0.999
Grade 1	10 (67)	10 (67)	20 (67)
Grade 2	3 (20)	4 (27)	7 (23)
Grade 3	2 (13)	1 (6)	3 (10)
Anemia, n (%)				0.330
Grade 1	6 (40)	2 (13)	8 (27)
Grade 2	5 (33)	8 (54)	13 (43)
Grade 3	4 (27)	5 (33)	9 (30)

Abbreviation: AE, adverse event.